Attovia Therapeutics
Steven Chan is an accomplished finance executive with extensive experience in the biotechnology and technology sectors. Currently serving as Chief Financial Officer at Attovia Therapeutics since October 2024, Steven previously held the CFO position at Connect Biopharma, overseeing financial strategy for a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases. Additional roles include CFO at Delphon, Vice President of Finance & Corporate Controller at Arcus Biosciences, where Steven played a key role in a $120M IPO, and similar positions at MyoKardia and Solta Medical, contributing to significant public transitions. Steven's career also encompasses leadership roles at Moody's Analytics, Polycom, Logitech, and Sun Microsystems. Educational qualifications include an Executive CFO degree from Columbia Business School and a Bachelor of Science in Business Administration from the University of California, Berkeley.
This person is not in any teams
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.